Johnson & Johnson $JNJ Stock: Sivik Global Healthcare LLC Increases Holdings

Sivik Global Healthcare LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 20.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,000 shares of the company’s stock after purchasing an additional 4,000 shares during the period. Johnson & Johnson accounts for about 3.9% of Sivik Global Healthcare LLC’s portfolio, making the stock its 3rd biggest holding. Sivik Global Healthcare LLC’s holdings in Johnson & Johnson were worth $6,354,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in JNJ. Outlook Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $28,000. Matrix Trust Co raised its stake in shares of Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after acquiring an additional 54 shares during the last quarter. Hyposwiss Advisors SA acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $42,000. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $43,000. Finally, Polaris Financial Partners bought a new stake in shares of Johnson & Johnson in the third quarter worth $56,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, September 22nd. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings raised Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday. Finally, Scotiabank restated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $276.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Adjusted third-quarter EPS was $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Management also raised its 2026 guidance, including a reported-sales midpoint of $101.2 billion and adjusted EPS midpoint of $11.10. Johnson & Johnson reports Q3 2026 results and raises guidance
• Positive Sentiment: Innovative Medicine remained the primary growth driver. TREMFYA sales reportedly rose 68% to $2.4 billion, and new long-term Crohn’s disease data support the drug’s expansion potential. The company also highlighted its OTTAVA surgical system and other pipeline and portfolio initiatives. TREMFYA long-term Crohn’s disease data
• Positive Sentiment: Johnson & Johnson declared a quarterly dividend of $1.34 per share, reinforcing its income-investment appeal. Johnson & Johnson quarterly dividend announcement
• Neutral Sentiment: Management is leaning toward spinning out its hips-and-knees business, a move that could sharpen the company’s focus but also highlights ongoing pressure in the medical-device portfolio. J&J hips-and-knees business spinoff report
• Negative Sentiment: GAAP profitability fell sharply: reported net earnings were approximately $210 million, or $0.09 per share, as special charges tied to the proposed talc litigation resolution, the Firefly Bio acquisition and Sail Biomedicines collaboration overshadowed the adjusted earnings beat. Johnson & Johnson quarterly report analysis
• Negative Sentiment: MedTech grew only 2.5% operationally and underperformed internal expectations, particularly in Cardiovascular and Surgery outside the United States. Reports also cited weaker surgery revenue and Middle East-related pressure on medical-device sales. J&J earnings and MedTech performance
• Negative Sentiment: Investors may view the guidance increase as modest relative to elevated expectations, while planned drug deals are expected to weigh on 2027 earnings. That reduced the market’s enthusiasm for the current-quarter beat and contributed to the stock’s decline. Johnson & Johnson 2027 earnings warning

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 6.2%

Shares of Johnson & Johnson stock traded down $16.34 on Tuesday, hitting $247.39. 6,586,227 shares of the company’s stock traded hands, compared to its average volume of 7,940,307. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company has a fifty day moving average of $266.01 and a two-hundred day moving average of $249.31. The company has a market capitalization of $596.19 billion, a price-to-earnings ratio of 28.65, a price-to-earnings-growth ratio of 2.65 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.80 earnings per share. As a group, sell-side analysts expect that Johnson & Johnson will post 11.18 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.